CREATING A PARADIGM SHIFT IN COMPLEX INTERVENTIONS IN PERIPHERAL AND CORONARY ARTERIAL DISEASES (PAD AND CAD)
We deliver a single-step, wire-free intraplaque crossing solution that modifies plaque and prepares the vessel for further treatment – all in one smooth move. It’s not an iteration. It’s a rewrite.
The AngioSafe Mission
AngioSafe was founded to flip the script in revascularization. Our technology doesn’t just improve the process – it replaces four families of devices, replicating outcomes and reducing complications.
We’re building a pipeline of game-changing devices that make complex interventions safer, faster and more predictable, while empowering physicians to more confidently address severely stenosed vessels, including chronic total occlusions (CTOs).
AngioSafe is the first philanthropic-funded medical device company in the world. Our investors are dedicated to fostering a better future for patients and communities and have committed to donating a percentage of their returns to various not-for-profit organizations around the world.
One Concept. All Cath Labs. All Interventionalists. Patented.
Flow Is Life. We Restore It.
Blood flow isn’t optional. It’s the first requirement for healing, limb salvage, and quality of life. But over 200 million patients are living with blocked vessels because traditional tools are just too slow, too risky, or too complex.
AngioSafe empowers more physicians to treat more patients—sooner, safer, and smarter.
Disruption Backed by Deep Experience.
We’re not new to this. Our founding team has shaped the industry—bringing first-in-class therapies to hundreds of millions of patients across respiratory, neurology, cardiovascular, vascular imaging, diagnostics, and orthopedic medicine, ranging from small start-ups to global multinational companies.
We’re bringing that same firepower to endovascular care. And we’re not stopping until no CTO goes untreated.
Our History
AngioSafe’s mission is personal yet global.
AngioSafe was founded with a clear and personal mission: to transform the way physicians treat the most challenging vascular occlusions. Our team set out to develop technologies that enable a safe approach allowing for more predictable restoration of blood flow. Established in 2015 and built on more than a decade of research and clinical collaboration, AngioSafe has now introduced its first system—Santreva-ATK, powered by our proprietary Atheroplasty technology—receiving both U.S. and EU marketing authorizations. While this marks an important company milestone, our commitment remains focused on a global goal: ensuring no patient is denied care because a vessel is considered too difficult to cross.
2015
Company Founded
2015
Company Founded
2016
Initial Product Designs
2016
Initial Product Designs
2017
Pre-Clinical Studies
2017
Pre-Clinical Studies
2018
First-in-Human Cases
2018
First-in-Human Cases
2019
Establish AngioSafe Clean Room
2019
Establish AngioSafe Clean Room
2020
Submit Santreva-ATK IDE to FDA
2020
Submit Santreva-ATK IDE to FDA
2021
Initiate RESTOR-1 Pivotal Trial for Santreva-ATK
2021
Initiate RESTOR-1 Pivotal Trial for Santreva-ATK
2022
Commercial Plant Construction
2022
Commercial Plant Construction
2023
Achieve ISO Certification for Facility
2023
Achieve ISO Certification for Facility
2025
CE Mark Approval, FDA Clearance for Santreva-ATK
2025
CE Mark Approval, FDA Clearance for Santreva-ATK
AngioSafe Leadership
AngioSafe is backed by a combined 200+ years of life science experience.
Sarvajna Dwivedi, Ph.D.
- President and CEO, Co-founder, Investor, Board Member
- Built Pearl Therapeutics to a $1.15B acquisition by AstraZeneca
- Deep experience in drug and device combination field
Mallik Thatipelli, MD
- Founder, Inventor, Chief of Innovation, and Board Member
- General surgeon, practicing endovascular physician
- A blend of interventional and engineering knowledge
Ram Reddy
- AngioSafe co-founder, Investor, and Board Member
- AngioSafe Board Chairman (2015-2025)
- Seasoned Silicon Valley investor, entrepreneur, global company builder
Sanjay Tripathi
- Founder and Managing Partner, Ananta Ventures
- Angiosafe Board Member
- Board Member, Pharmanova and Atlantic Lifesciences
Clinical Advisors
Driven by patients, guided by physicians, we are transforming the future of vascular intervention.
Subhash Banerjee, M.D., FACC, FSCAI
- National Principal Investigator, AngioSafe Peripheral program
- Chief of Cardiovascular Research and Innovation for Baylor Scott & White Heart and Vascular Hospital
Peter Soukas, M.D., FACC, FSCAI, FSVM, FACP, RPVI
- Director of Vascular Medicine and the Interventional Vascular Laboratories, The Miriam and Rhode Island Hospitals, Brown University Providence, RI
Ashish Pershad, M.D.
- National Principal Investigator, AngioSafe Coronary program
- Director of Cardiology, Interventional Cardiology Dignity Health Chandler, AZ
Venkatesh Ramaiah, M.D., FACS
- Founder, Vascular Surgeon, Pulse Cardiovascular Institute Phoenix, AZ